Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Supernus Pharm (NQ: SUPN ) 36.18 -1.59 (-4.21%) Streaming Delayed Price Updated: 4:00 PM EST, Nov 14, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Supernus Pharm < Previous 1 2 3 4 5 Next > Supernus Pharmaceuticals to Announce Second Quarter 2022 Financial Results and Host Conference Call on August 4, 2022 July 25, 2022 From Supernus Pharmaceuticals, Inc. Via GlobeNewswire FDA Approves Expanded Use Of Supernus' Viloxazine In Adult ADHD Patients May 02, 2022 Via Benzinga Attention Biotech Investors: Mark Your Calendar For May PDUFA Dates May 01, 2022 The month of April was a mixed one for regulatory approvals. The Food and Drug Administration delayed approvals for at least three treatment candidates. New molecular entity, or NME, approvals, a... Via Benzinga The Daily Biotech Pulse: FDA Approves Bristol Myers' Oral Heart Disease Drug, European Approval For Merck's Keytruda, Genocea Restructures, Zymeworks' Takeover Bid April 29, 2022 Here's a roundup of top developments in the biotech space over the last 24 hours. Via Benzinga Earnings Scheduled For February 28, 2022 February 28, 2022 Companies Reporting Before The Bell • Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to report earnings for its fourth quarter. • Praxis Precision Medicine (... Via Benzinga The Week Ahead In Biotech (April 24-April 30): Bristol-Myers Squibb, Supernus, Hutchmed, Axsome, Coherus FDA Decisions, Big Pharma Earnings, IPOs And More April 24, 2022 Biotech stocks extended their loses in the week ending April 22. The sector took cues from the broader market, which reacted to the lackluster start of the first-quarter reporting season and lingering... Via Benzinga Looking Into Supernus Pharmaceuticals's Return On Invested Capital April 14, 2022 According to Benzinga Pro data Supernus Pharmaceuticals (NASDAQ:SUPN) posted a 88.67% decrease in earnings from Q3. Sales, however, increased by 7.13% over the previous quarter to $159.05 million. Via Benzinga Supernus Pharmaceuticals Stock Sees Relative Strength Rating Jump To 92 April 07, 2022 On Thursday, Supernus Pharmaceuticals stock earned an upgrade to its Relative Strength (RS) Rating, from 87 to 92. Via Investor's Business Daily Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates April 01, 2022 Biopharma stocks are sensitive to a key binary event called the PDUFA date, the date by which the Food and Drug Administration is required to give its verdict on a regulatory application filed with... Via Benzinga The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight February 27, 2022 Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first... Via Benzinga Supernus (SUPN) Moves 5.7% Higher: Will This Strength Last? February 21, 2022 Supernus Pharmaceuticals shares soared 5.7% in the last trading session to close at $32.90. The move was backed by solid volume with far more shares changing hands than in a normal session. Via Talk Markets Top Ideas in the Small Cap Biotech Space (LEXTF, ABBV, SAVA, SNDL, RETA, PAHC) January 24, 2022 Via AB Newswire The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO November 04, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck's Oral Antiviral COVID-19 Pill Authorized In UK Merck &... Via Benzinga Exposures COVID-19 Supernus Pharmaceuticals, inc (SUPN) Q3 2021 Earnings Call Transcript November 04, 2021 SUPN earnings call for the period ending September 30, 2021. Via The Motley Fool Topics Earnings Exposures Financial Supernus Pharmaceuticals: Q3 Earnings Insights November 03, 2021 Supernus Pharmaceuticals (NASDAQ:SUPN) reported its Q3 earnings results on Wednesday, November 3, 2021 at 04:00 PM. Here's what investors need to know about the announcement.... Via Benzinga The Daily Biotech Pulse: Cerus Climbs On Earnings, Horizon CFO To Retire, Teva Prices Upsized Sustainability-Linked Senior Note Offering November 03, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Horizon Announces Retirement Of CFO, Beat-and-raise Q3 Horizon Therapeutics... Via Benzinga Topics Retirement Exposures Pension Why Supernus' Acquisition of Adamas Is a Smart Move October 21, 2021 Adamas looks like a good fit for Supernus. Via The Motley Fool Mid-Afternoon Market Update: Dow Tumbles Over 100 Points; Flexion Therapeutics Shares Spike Higher October 11, 2021 Toward the end of trading on Monday, the Dow traded down 0.37% to 34,617.17 while the Nasdaq fell 0.05% to 34,617.14. The S&P 500 also fell, dropping 0.26% to 4,379.88. Let's look at what has happened... Via Talk Markets Topics Stocks Exposures US Equities Earnings Scheduled For November 3, 2021 November 03, 2021 Companies Reporting Before The Bell • R.R.Donnelley & Sons (NYSE:RRD) is likely to report quarterly earnings at $0.32 per share on revenue of $1.19 billion.... Via Benzinga The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline October 31, 2021 Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc... Via Benzinga Mid-Afternoon Market Update: Dow Tumbles Over 100 Points; Flexion Therapeutics Shares Spike Higher October 11, 2021 Toward the end of trading Monday, the Dow traded down 0.37% to 34,617.17 while the NASDAQ fell 0.05% to 34,617.14. The S&P also fell, dropping 0.26% to 4,379.88. The U.S. has... Via Benzinga Topics Stocks Exposures US Equities Mid-Day Market Update: Crude Oil Surges Over 2%; Supernus Pharmaceuticals To Acquire Adamas Pharmaceuticals October 11, 2021 Midway through trading Monday, the Dow traded up 0.50% to 34,920.55 while the NASDAQ rose 0.50% to 34,920.55. The S&P also rose, gaining 0.44% to 4,410.73. The U.S. has the... Via Benzinga Topics Stocks Exposures Fossil Fuels US Equities ADMS Stock Soars 70% Thanks to Adamas Pharmaceuticals Acquisition News October 11, 2021 ADMS stock is seeing huge gains this morning as it announces a planned merger with fellow biopharma company Supernus worth $400 million. Via InvestorPlace Supernus Bolsters Parkinson's Portfolio With $450M Adamas Buyout: Highlights October 11, 2021 Supernus Pharmaceuticals Inc (NASDAQ: SUPN) has agreed to acquire Adamas Pharmaceuticals Inc (NASDAQ: ADMS) for $9.10 per share, or $450 million. The deal... Via Benzinga Novavax Appoints New CFO Amid Inordinate Delay In COVID-19 Vaccine Authorization August 16, 2021 Novavax, Inc. (NASDAQ: NVAX) announced new hires to its executive team even as it is stymied by the delay in getting authorization for its COVID-19 vaccine in the U.S. What... Via Benzinga Exposures COVID-19 Supernus Pharmaceuticals, inc (SUPN) Q2 2021 Earnings Call Transcript August 04, 2021 SUPN earnings call for the period ending June 30, 2021. Via The Motley Fool Topics Earnings Exposures Financial The Daily Biotech Pulse: Biogen Faces Another Clinical Setback, CureVac's COVID-19 Vaccine Study Fails, Moment Of Reckoning For Orphazyme June 17, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 16) Alexion Pharmaceuticals,... Via Benzinga Exposures COVID-19 Earnings Scheduled For August 4, 2021 August 04, 2021 Companies Reporting Before The Bell • UroGen Pharma (NASDAQ:URGN) is projected to report earnings for its second quarter. • Vericel (NASDAQ:VCEL) is expected to... Via Benzinga Biotechs Ready To Roar June 13, 2021 The biggest event last week was the FDA decision to approve Biogen's drug aducanumab, a treatment for Alzheimer's disease. The decision will reverberate across the industry and the healthcare sector... Via Talk Markets Exposures Product Safety Supernus Pharmaceuticals Stock Getting Closer To Key Technical Measure June 10, 2021 A Relative Strength Rating upgrade for Supernus Pharmaceuticals shows improving technical performance. Will it continue? Via Investor's Business Daily < Previous 1 2 3 4 5 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
